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Abstract: p130cas (p130 Crk-associated substrate) is a scaffolding protein and plays an important role in regu-
lating focal adhesion and driving cell migration. Also, the destruction of the E-cadherin/b-catenin adhesive
complex is one of the changes that characterizes the invasive phenotype of tumors. The aim of this study is to
evaluate the role of p130cas, E-cadherin, and b-catenin expression in patients with non-small cell lung cancer
(NSCLC). We examined the expression of p130cas, E-cadherin, and b-catenin in 105 lung cancer tissues and
paired adjacent normal lung tissues using immunohistochemistry. The overexpression of p130cas was observed
in 61.9% (65/105) of lung cancer samples. The overexpression of p130cas was correlated with abnormal expres-
sion of E-cadherin and b-catenin (p = 0.002 and p = 0.006, respectively). Chi-square test showed that the
overexpression of p130cas correlated positively with lymph node metastasis and high TNM stage. The Log-
Rank test revealed that the mean survival time of patients with p130cas overexpression (36.31 ± 5.66 months)
was markedly shorter than that of those with p130cas normal expression (60.57 ± 6.95 months). Multivariable
analysis indicated p130cas overexpression (p < 0.001) to be an independent significant prognostic factor for
NSCLC patients’ survival. These results indicate that p130cas may impact a variety of clinicopathological fea-
tures of NSCLC and may influence the prognosis of lung cancer patients. (Folia Histochemica et Cytobiologica
2012, Vol. 50, No. 3, 392–397)
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Introduction
Lung cancer is a leading cause of cancer death world-
wide [1]. Non-small cell lung cancer (NSCLC) ac-
counts for nearly 85% of all cases of lung cancer [2].
Unfortunately, most patients with NSCLC are diag-
nosed in an advanced stage with local or distant me-
tastases [3]. Therefore, identification of biomarkers
for predicting metastasis and prognosis is urgently
needed for the treatment of NSCLC.
p130cas (p130 Crk-associated substrate) is the
product of BCAR1 (breast cancer anti-estrogen re-
sistance 1) gene, which is the premier member of the
CAS (Crk-associated substrate) scaffold protein fam-
ily [4]. p130cas was first described as a heavily tyrosine-
phosphorylated component of v-Src and v-Crk trans-
formed cells [5–7]. p130cas itself has no intrinsic ki-
nase activity, but instead functions as a signal assem-
bler [4, 8, 9]. Recent studies have demonstrated that
p130cas regulates focal adhesion turnover and plays
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an important role in driving cell migration [10–12].
Although its expression in tissues and cell lines has
been investigated in multiple malignancies [13–16],
the relationship between p130cas expression and lung
cancer patients’ clinicopathological parameters, par-
ticularly prognosis, remains largely unknown.
E-cadherin and b-catenin, which form an adhe-
sion complex, are specifically involved in epithelial
cell-to-cell adhesion. During the development of can-
cer, the destruction of the E-cadherin/b-catenin com-
plex is one of the changes that characterizes the inva-
sion phenotype [17, 18]. Some recent studies have
raised the possibility that p130cas might influence
E-cadherin/b-catenin expression. A 2008 clinico-
pathological study of E-cadherin and p130cas in hepa-
tocellular carcinoma identified a negative correlation
between the expression of these two proteins, while
another report demonstrated that p130cas negative-
ly regulated E-cadherin/b-catenin membrane local-
ization and promoted E-cadherin degradation in
breast cancer cell lines [19]. However, to the best of
our knowledge, there has been no published informa-
tion discussing the correlations between p130cas expres-
sion and E-cadherin/b-catenin expression in NSCLC.
The aim of this study was to analyze p130cas ex-
pression in NSCLC, and to evaluate whether the pres-
ence of p130cas correlates with the expression of
E-cadherin/b-catenin and with clinicopathological fea-
tures.
Material and methods
Material. We selected 105 cases of lung squamous cell car-
cinoma and lung adenocarcinoma, with corresponding nor-
mal lung tissues, collected and diagnosed at the First Affil-
iated Hospital of China Medical University (Shenyang,
China) between October 2004 and July 2006. The samples
were from 63 male and 42 female patients with an average
age of 60.4 years. According to the World Health Organiza-
tion (WHO) lung tumor histological classification criteria
(2004) [20], the samples were classified as lung squamous
cell carcinoma (43 cases) or lung adenocarcinoma (62 cas-
es). Thirty-six cases were highly (G1) or moderately (G2)
differentiated, and 69 cases were poorly (G3) differentiat-
ed. In addition, there were lymph node metastases in 64
cases, but not in the other 41. Tumor staging was performed
according to the seventh edition of TNM for Lung Cancer
of the International Union against Cancer (UICC) [21].
There were 46 cases of stage I–II, and 59 cases of stage IIIa–
IIIb. Patient survival was counted from the day of the oper-
ation to the end of follow-up or to the day the patient died
from recurrence or metastasis. All patients had no radio-
therapy or chemotherapy before the operation, and were
given the standard treatment following the surgery. All sam-
ples were fixed in formalin, embedded in paraffin, and
stained with hematoxylin and eosin for pathological analy-
sis, to make the diagnosis.
Immunohistochemistry and evaluation of immunostaining.
Surgically excised tumor specimens were fixed with 10%
neutral formalin and embedded in paraffin, and 4-μm thick
continuous sections were prepared. Normal bronchial epi-
thelium present in the tumor slides was used as an internal
positive control. Immunostaining was performed by the
streptavidin-peroxidase (S-P) method. The sections were in-
cubated with the monoclonal antibody ab31831 (1:250;
Abcam, Cambridge, MA, USA) to detect p130cas, the mon-
oclonal antibody sc-8426 (1:150; Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA) to detect E-cadherin, or the
monoclonal antibody 610154 (1:200; BD Transduction Lab-
oratories, Lexington, KY, USA) to detect b-catenin, at 4°C
overnight. Biotinylated goat anti-mouse serum IgG (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used
as a secondary antibody. After washing, the sections were
incubated with streptavidin–biotin conjugated with horse-
radish peroxidase (Ultrasensitive, MaiXin, Fuzhou, Chi-
na), and the peroxidase reaction was developed with
3,3-diaminobenzidine tetrahydrochloride (MaiXin,
Fuzhou, China). Counterstaining was done lightly with he-
matoxylin, and the sections were dehydrated in alcohol be-
fore being mounted.
Two investigators, who were unaware of the clinical data,
examined all the tumor slides randomly. Five views were
examined per slide, and 100 cells were observed per view,
at magnification × 400. The cytoplasmic p130cas labeling
score was defined by multiplying the percentage of positive
cells by the staining intensity. The percentage of positive
cells was scored as follows: 0 = 0–25%; 1+ = 26–50%;
2+ = 51–75%; and 3+ = 76–100%.
The staining intensity was scored as follows: 0 = nega-
tive; 1 = weak; 2 = moderate; and 3 = strong. When the
p130cas score was more than 3 points, the case was defined
as positive; when it was equal to or less than 3 points, the
case was defined as negative. The E-cadherin and b-cate-
nin scores were determined by the percentage of membra-
nous positive cells per slide, as in our previous study [22,
23]. When more than 90% of the tumor cells were stained
for E-cadherin or b-catenin in the cell membrane, the case
was defined as normal membranous expression. When few-
er than 90% of the tumor cells were stained for membra-
nous expression, the case was defined as loss of expression.
Statistical analysis. All statistical analyses were performed
using SPSS for Windows 17.0. Results from immunohis-
tochemistry were analyzed by the Chi-square test and Spear-
man correlation test. For survival analysis, the Log-Rank
test was used. Survival curves were computed according to
the Kaplan–Meier method. The Cox regression model was
used to test the prognostic value. A p-value of less than 0.05
was considered statistically significant.
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Expression pattern of p130cas, E-cadherin
and b-catenin
p130cas was overexpressed in the cytoplasm of lung can-
cer cells. The positive expression rate of p130cas in nor-
mal bronchial epithelium (Figure 1A) was lower than in
cancer tissue (Figures 1D, G) (9.5% and 61.9%, respec-
tively; p < 0.001). The membranous expression of
E-cadherin was  downregulated in lung cancer sam-
ples. The normal expression rate of E-cadherin was high-
er in normal bronchial epithelium (Figure 1B) than
in cancer tissue (Figures 1E, H) (100% and 33.3%,
respectively; p < 0.001). The membranous expression of
b-catenin was decreased significantly in lung cancer sam-
ples. The normal membranous expression rate of b-cate-
nin in normal bronchial epithelium (Figure 1C) was high-
er than in cancer tissue (Figures 1F, I) (86.7% and 17.1%,
respectively; p < 0.001).
p130cas overexpression correlated with abnormal
expression of E-cadherin and b-catenin
in non-small cell lung cancer
In 105 NSCLC samples, the correlation between
p130cas overexpression and loss of E-cadherin and
b-catenin expression are shown in Table 1. The over-
expression of p130cas was correlated with abnormal
expression of E-cadherin and b-catenin (p = 0.004,
r = 0.301 for E-cadherin and p = 0.006, r = 0.268 for
b-catenin, respectively).
Relationship between p130cas and clinicopathological
parameters of non-small cell lung cancer
In 105 NSCLC samples, the overexpression of p130cas
correlated positively with lymph node metastasis and
high TNM stage (p = 0.001, r = 0.337 for lymph node
metastasis and p = 0.027, r = 0.268 for TNM stage,
respectively). However, there were no statistically
Figure 1. Immunohistochemistry reveals the localization of p130cas, E-cadherin and b-catenin. In normal bronchial
epithelium, p130cas was negatively or weakly stained in the cytoplasm (A); E-cadherin stained strongly at the cell mem-
brane (B); b-catenin stained strongly at the cell membrane (C); When p130cas was found moderately or strongly stained
in lung adenocarcinoma (D) and squamous cell carcinoma (G); E-cadherin was also absent or weakly stained at the
membrane in lung adenocarcinoma (E) and squamous cell carcinoma (H); b-catenin was absent or weakly stained at the
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significant differences between overexpression of p130cas
and sex, age, histology type or differentiation (Table 2).
The Log-Rank test revealed the difference in the
survival time of patients between overexpression of
p130cas and normal expression of p130cas
(p < 0.001, Figure 2). The mean survival time of pa-
tients with p130cas overexpression (36.31 ± 5.66
months) was markedly shorter than that of patients with
p130cas normal expression (60.57 ± 6.95 months). Sub-
sequently, all the clinicopathological parameters
were entered into the Cox model and tested by
univariate survival analysis (the enter method) and
multivariate survival analysis (the forward stepwise
logistic regression method) (Table 3). The univari-
ate survival analysis indicated that TNM stage, his-
tology type and overexpression of p130cas were sig-
nificantly associated with poor prognosis in NSCLC
patients (p = 0.005 for TNM stage, p = 0.044 for
histology type and p = 0.001 for p130cas overexpres-
sion, respectively). Based on the multivariate sur-
vival analysis, only p130cas overexpression played
a significant role in the clinical outcome (p < 0.001).
p130cas overexpression was thus considered as an
independent and effective predictor of prognosis in
NSCLC patients.
Discussion
p130cas, introduced by Sakai in 1990 and originally
identified as a highly phosphorylated protein in cells
transformed by the v-Src and v-Crk oncogenes, is
a scaffolding protein at focal adhesion known to be over-
expressed in cancer cells and to be associated with sol-
id tumor metastasis [5–7, 9]. In the present study, we
demonstrated the p130cas is expressed in the cytoplasm
and overexpressed in lung cancer tissue (61.9%, 65/
/105), which is significantly higher than that in paired
adjacent normal lung tissue (9.5%, 10/105; p < 0.001).
Table 1. Correlations between p130cas overexpression and abnormal expression of E-cadherin and b-catenin
p130cas expression c2 r p
Normal Increased
E-cadherin expression Normal 20 15 8.077 0.301 0.004
Abnormal 20 50
b-catenin expression Normal 12 6 7.520 0.268 0.006
Abnormal 28 59
Table 2. Correlation of p130cas overexpression with clinicopathological parameters in NSCLC
Item Number p130cas c2 r p
overexpression
Gender
Male 63 42 1.514 –0.120 0.218
Female 42 23
Age (years)
    < 60 47 30 0.134 –0.36 0.715
    ≥ 60 58 35
Histology type
Squamous cell carcinoma 43 27 0.024 –0.015 0.876
Adenocarcinoma 62 38
Lymph node metastasis
Negative 41 17 11.918 0.337 0.001
Positive 64 48
Differentiation
High 36 19 1.935 –0.136 0.164
Moderate or poor 69 46
TNM classification
I–II 46 23 4.920 0.216 0.027
IIIa–IIIb 59 42
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Figure 2. Survival curve of patients with p130cas
overexpression. Kaplan–Meier curves demonstrate that
overexpression of p130cas was positively correlated with
the overall survival of patients with NSCLC (p < 0.001)
Table 3.
A. Overall survival in Cox regression analysis in NSCLC
B. Independent predictor of overall survival in Cox regression in NSCLC
Factors Regression coefficient Wald chi-square test p Risk ratio
A
Gender 0.197 0.507 0.476 1.218
Age 0.019 0.005 0.943 1.020
Differentiation -0.459 2.446 0.118 0.632
TNM classification 1.445 7.729 0.005 4.240
Histological type 0.564 4.072 0.044 1.757
Lymph node metastasis –0.954 3.307 0.069 0.385
p130cas 1.090 11.231 0.001 2.975
E-cadherin –0.045 0.021 0.885 0.956
b-catenin 0.334 0.545 0.461 1.396
B
p130cas 1.035 11.988 0.001 2.816
The results of this study are consistent with most
existing studies showing that p130cas is expressed in
the cytoplasm and function at the focal adhesion. Nev-
ertheless, Deng et al. revealed that p130cas was stained
in cytoplasm and/or nuclear and positively expressed
in 98.8% (79/80) of NSCLC samples and 12.5% (10/
80) of normal adjacent lung tissues [14]. The distinc-
tion of subcellular distribution and positive rate of
p130cas in lung carcinoma between that study and ours
might contribute to the difference of primary anti-
body selection and evaluating standard. Therefore,
the precise expression pattern of p130cas in NSCLC
is still being investigated.
E-cadherin and b-catenin as a complex are specif-
ically involved in the regulation of epithelial cell-to-
-cell adhesion and have a close relationship with the
invasion ability of cancer. The E-cadherin/b-catenin
complex is often destroyed during the process of car-
cinogenesis [17]. In our study, we showed that over-
expression of p130cas was significantly correlated with
loss of membranous E-cadherin/b-catenin expression.
Previous studies have demonstrated that p130cas was
functioned at the focal adhesion, and recent reports
have revealed that p130cas was involved in negative
regulation of E-cadherin membrane localization in
breast cancer cell lines and correlated with loss of
E-cadherin/b-catenin expression in hepatocellular car-
cinoma [4, 15, 19, 24]. These studies and our results
suggest that p130cas may play a critical role in cell-
to-cell adhesion through its interaction with
E-cadherin/b-catenin complex.
Subsequently, we tested the associations between
p130cas and clinicopathological parameters. We
found that the overexpression of p130cas was corre-
lated positively with lymph node metastasis and high
TNM stage in NSCLC samples. More importantly,
we also examined the relationship between p130cas
protein expression and the prognosis of NSCLC pa-
tients. The results revealed that p130cas overexpres-
sion significantly correlated with poor survival of
NSCLC patients. Cox regression model demonstrat-
ed that p130cas overexpression can be an indepen-
dent factor that impacts lung adenocarcinoma pa-
tients’ prognosis. The expression of p130cas has been
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extensively studied in breast cancer and has been
linked with proliferation, metastasis, poor prognosis
and tamoxifen resistance. Similarly, overexpression
of p130cas has been observed in hepatocellular car-
cinoma, prostate carcinoma and ovarian carcinoma,
which were correlated with high tumor stage, metasta-
sis and inverse clinical outcome.
However, to the best of our knowledge, there have
been no reports discussing the relationship between
p130cas expression and clinicopathological parame-
ters in NSCLC. Our findings are consistent with these
reports and suggest a positive correlation of overex-
pression of p130cas with lymph node metastasis and
poor prognosis in NSCLC. It should be noted that
this study has examined p130cas expression only in a
relatively small sample size. Therefore, larger-scale
studies are needed to further confirm the function of
p130cas in NSCLC.
In conclusion, p130cas is overexpressed in NSCLC
samples. The overexpression of p130cas is correlated
with the loss of membranous E-cadherin/b-catenin
expression. Furthermore, overexpression of p130cas
is linked to positive lymph node metastasis and high
TNM stage in NSCLC samples. More importantly,
p130cas overexpression indicates a poor prognosis in
NSCLC patients.
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